|
 The medical device maker intends to launch Eluvia in the fourth
quarter, Jeff Mirviss, president of Boston Scientific's Peripheral
Interventions division, told Reuters.
Eluvia, approved in Europe since 2016, targets the 8.5 million
people in the United States who suffer from peripheral artery
disease (PAD), a painful condition caused by plaque buildup in the
arteries of the limbs. If left untreated, the condition could result
in an amputation.
The company estimates the global market size to be upwards of $1
billion, Mirviss said.
Eluvia is a tiny wire mesh scaffolding with a drug-polymer coating
that releases paclitaxel, an existing chemotherapy drug, for about a
year to prevent reclogging.
Data from a trial in 475 patients showed Eluvia was more effective
over a year than privately held Cook Medical's Zilver PTX stent, the
only rival drug-eluting stent currently available, according to
Boston Scientific.
Only 1 in 20 patients on Eluvia required a repeat procedure,
compared with roughly 1 in 10 that used Zilver.
[to top of second column] |
"Eluvia releases the drug over a year...the Cook Zilver PTX stent
releases drug for only about 60 days. And so that, we believe, is
why we're seeing the superior results," Mirviss said.
Unlike heart stents, which have been in use for over a decade,
stents made for arteries in the leg have to contend with larger
blood vessels and the need to be flexible to accommodate for
movement.
Eluvia is also expected to rival other technologies including
drug-coated balloons and bare-metal stents, Boston Scientific said.
(Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj
Kalluvila)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
